Clinical Analysis Of 241 Mutiple Myeloma Patients With Related Organor Tissue Impairment

Objective:To investigate the incidence of multiple myeloma (MM) patients with related organor tissue impairment(ROTI) and the relationship between ROTI and different immunotype, clinical stage,and the chemotherapy curative effect.Mtethods:To analyse the feasibility of clinical features of 241 MM patients in the first affiliated hospital of Guangxi Medical University during August 2010 to August 2015.Results: ①The total incidence rate of MM patients with ROTI was 96.3%.The incidence rate of four kinds of ROTI including skeletal disease, anemia, renal insufficiency and hypercalcemia is 90.0%,72.2%,41.9% and 90.0% respectively.②71-80 years old multiple myeloma group had a significantly higher incidence rate of renal insufficiency than 41 to 50 years old group,51 to 60 years old, and61-70 age group.(92.3% vs.12.2%,40.3%, 42.1%, P<0.01)③The incidence rate of anemia among patients diagnosed on stage Ⅲ according to Durie-Samon is significantly higher than the group of the on stage I and II (77.7% vs. 1.1%,50.0%, P<0.05).The incidence rate of skeletal disease among patients diagnosed on stage III according to Durie-Samon is significantly higher than the group of the on stage 1(92.2% vs.66.7%, P<0.05).④MM among group B according to Durie-Samon had a significantly higher incidence rate of hypercalcemia than MM among group A (10.9% vs.4.3%, P<0.05).⑤Light chain multiple myeloma(LCMM) had a significantly higher incidence rate of anemia than IgG and IgA type multiple myeloma (78.8% vs.60.0%,51.3%, P<0.05).IgG type multiple myeloma g had a significantly higher incidence rate of skeletal disease than LCMM and IgA type multiple myeloma (95.0% vs. 75.8%,84.4%, P<0.05)⑥MM with moderate and severe anemia had a significantly lower overall response rate (ORR)to chemotherapy curative effect containing Bortezomib than MM patients with the mild anemia group. (52.2% vs.72.7%, P=0.03).Conclusions:①There is a high incidence rate of MM patients with ROTI.②MM patients with ROTI was correlated with the different immunotype and clinical stage.③MM with moderate and severe anemia has a poor response to chemotherapy curative effect containing Bortezomib.